Related Experiment Video
Updated: Feb 4, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Variability in Phelan-McDermid syndrome: The impact of the PNPLA3 p.I148M polymorphism
Luigi Boccuto1, Ludovico Abenavoli2, Lauren Cascio1
1Greenwood Genetic Center, Greenwood, South Carolina.
Abstract:
The PNPLA3 gene maps in the 22q13 region and can have modifying effects on the phenotype of patients with Phelan-McDermid syndrome (PMS). The PNPLA3 p.I148M variant was detected in two PMS patients presenting with refractory seizures, gastrointestinal issues, and liver dysfunction. The p.I148M variant leads to macrovescicular steaosis and predisposes to liver disorders from steatohepatitis to fibrosis. Accumulation of lipid macrovescicles in the hepatocytes affects several pathways, including the metabolismof anti-epileptics, possibly leading to the lack of response to anti-epileptic treatments reported in the two cases. Screening for the p.I148M variant can identify PMS patients at higher risk for liver dyfunction and help designing personalized therapeutic protocols.
Insights
The PNPLA3 p.I148M variant in Phelan-McDermid syndrome (PMS) patients is linked to liver issues and refractory seizures. Identifying this variant aids in personalized treatment for liver dysfunction and epilepsy.
Area of Science:
- Genetics
- Hepatology
- Neurology
Background:
- Phelan-McDermid syndrome (PMS) is a genetic disorder associated with chromosome 22q13 deletions.
- The Patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene plays a role in lipid metabolism and liver health.
Observation:
- The PNPLA3 p.I148M variant was identified in two PMS patients with severe symptoms.
- These patients exhibited refractory seizures, gastrointestinal problems, and liver dysfunction.
Findings:
- The PNPLA3 p.I148M variant is associated with macrovesicular steatosis, increasing susceptibility to liver conditions like steatohepatitis and fibrosis.
- Lipid accumulation in hepatocytes may impact anti-epileptic drug metabolism, potentially explaining treatment resistance.
Implications:
- Screening for the PNPLA3 p.I148M variant can identify PMS patients at elevated risk for liver disease.
- This genetic information can guide the development of personalized therapeutic strategies for PMS patients, particularly for managing liver complications and refractory epilepsy.
Related Concept Videos
Impact of Groups on Groups
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...
Single Nucleotide Polymorphisms-SNPs
Graphs of Equations in Two Variables
Variables Affecting Phosphorescence and Fluorescence

